Search PubMed⌕ Search

Biomedical subjects

F Tejada

Publications and source records attributed to F Tejada.

31 records · Page 2Linked to original sources
PubMed1979

Vincristine effect on methotrexate cerebrospinal fluid concentration.

A 67-year-old man with malignant lymphoma, nodular, poorly differentiated lymphocytic type, developed meningeal lymphomatosis. Repeated high-dose methotrexate-citrovorum factor treatment (1 g/m2 in 24 hours) rendered the patient free of disease. The administration of vincristine at 23 hours consistently increased the concentration of methotrexate in the cerebrospinal fluid 2.5-fold above baseline values.

Aged↗
PubMed1978

Adjuvant whole-lung radiation with or without adriamycin treatment in osteogenic sarcoma.

Eighteen consecutive patients with osteogenic sarcoma were treated after initial surgery with 2000 rads of whole-lung radiation for 21--28 days. Eleven of these patients went on to receive adriamycin (20 mg/m2 X 3 days every 6 weeks). Three of seven evaluable patients are free of disease in the radiation group (median time to recurrence, 130 days) while six of ten evaluable patients are free of disease in the radiation + adriamycin group (median time to recurrence, 310+ days). These results are similar to published experience with whole-lung radiation and adriamycin alone.

Adolescent↗
PubMed1977

Placental proteins and their subunits as tumor markers in prostatic carcinoma.

Sixteen patients with Stage D adenocarcinoma of the prostate were prospectively evaluated for the presence of human placental lactogen (hPL), placental alkaline phosphatase (PAP), and human chorionic gonadotropin (hCG). Ectopic production of hCG was found in one of the 16 cases and is described in detail. Serial serum hCG levels in that patient mirrored his course more reliably than concomitant acid phosphatase levels. Serum estradiol, testosterone, the hCG-alpha subunit, hPL and PAP were not elevated. There was a minimal elevation of serum FSH. There were no elevations of the other placental proteins in ten evaluable cases. A retrospective evaluation of serum bank specimens from 47 patients with prostatic carcinoma revealed no elevation of the placental proteins hPL, hCG-beta, and hCG-alpha. To our knowledge this report documents the first case of a chorionic gonadotropin-producing prostatic carcinoma appearing the literature.

Adenocarcinoma↗
PubMed1977

Cardiac metastases in lung cancer.

Cardiac metastases from bronchogenic carcinoma are not commonly diagnosed prior to death. This study isolates factors associated wtih the development of cardiac involvement. Four hundred eighteen consecutive patients with lung cancer who had autopsies were studied. Twenty-five percent of these patients had cardiac involvement. Factors associated with cardiac metastases were (1) histologic cell type of the tumor, (2) aggressive therapy, (3) extent of disease, and (4) tumor differentiation. The presence of cardiac metatases was not related to the length of survival. Clinical signs of cardiac involvement included an enlarging heart on the chest x-ray film, development of congestive heart failure, or electrocardiographic changes. Suspicion of cardiac metastases in high-risk individuals, prompt diagnostic evaluation, and rapid institution of therapy may improve the outlook for many patients, since reaccumulation of fluid was generally slow.

Adenocarcinoma↗
PubMedDate not supplied

Phase I clinical trial of isophosphamide (NSC-109724).

An initial clinical phase I trial of isophosphamide has been carried out at dose levels of 200-10,000 mg/m2 of body surface area using a single-dose, every-3-week schedule. Significant toxicity was not seen at isophosphamide dose levels less than 2900 mg/m2. At higher doses, nausea and vomiting was nearly universal. Hematologic toxicity manifested by leukopenia occurred in 12 of 20 patients treated with doses of 3800-7000 mg/m2. Thrombocytopenia to 100,000 platelets/mm3 was not seen in any patient. Urinary bladder toxicity manifested by hemorrhagic cystitis was seen in 15 of 23 patients treated with doses of 3800-10,000 mg/m2. Hemorrhagic cystitis could be completely prevented by bladder irrigation with N-acetyl-L-cysteine (1% solution, 2000 ml/day). With careful attention to hydration, renal toxicity was largely prevented with blood urea nitrogen elevations to 30 mg/dl in only two of 14 patients receiving isophosphamide doses of 5000-7000 mg/m2. Another side effect was central nervous system toxicity in seven of 17 patients at doses of 5000-10,000 mg/m2. For phase II trials a dose of 5000 mg/m2 is recommended, with careful attention to the state of hydration in the patient and with the knowledge that bladder irrigation may be necessary for the prevention and/or amelioration of bladder toxicity.

Adenocarcinoma↗
PubMedDate not supplied

Initial chemotherapeutic trials in patients with inoperable or recurrent cancer of the prostate.

This paper describes a random study being conducted to compare the value of 5-fluorouracil plus diethylstilbestrol vs diethylstilbestrol alone and the value of 5-fluorouracil vs CCNU in the treatment of stage D adenocarcinoma of the prostate. We have established that similar normal values of acid phosphatase are encountered in serum and bone marrow of patients with nonmalignant and malignant diseases without osseous metastasis.

Acid Phosphatase↗
PubMedDate not supplied

Phase I study of thalicarpine (NAC-68075), a plant alkaloid of noval structure.

An initial clinical trial of daily and weekly X 6 ihtravenous infusions of thalicarpine, a plant alkaloid of novel structure, was carried out in 36 patients. Twenty-eight patients received 33 courses of single-dose administration at doses of 200-1900 mg/m2. At the maximum tolerable dose of 1400 mg/m2, toxic effects included arm pain (nine or ten), central nervous system depression (seven of ten), nausea and vomiting (two of ten), hypotension (two of ten), hypertension (two of ten), arrhythmia (premature ventricular contractions) (one of ten), and electrocardiographic changes (mainly T-wave flattening) (five of ten). At the maximum tolerable dose for weekly administration, 1100 mg/m2/week X 6, arm pain was seen in seven of eight, central nervous system depression in three of eight, hypotension in one of eight, and electrocardiographic changes in three of eight. The recommended dose for phase II trials is 1100 mg/m2/week by a 2-hour intravenous infusion.

Adult↗
PubMedDate not supplied

Pulmonary function tests during adjuvant lung irradiation for osteogenic sarcoma.

Six patients received whole-lung irradiation at a dose of 2000 rads/4 weeks (nominal standard dose = 700 Rets) after surgery for primary osteogenic sarcoma. Pulmonary function tests performed before and 6-20 months after pulmonary irradiation failed to demonstrate any pulmonary function impairment in any of the patients studied.

Adolescent↗